|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 69.92 EUR | +1.49% |
|
+2.42% | +9.74% |
| 06-23 | Orion's Investigational Drug Wins EU Orphan Drug Designation to Treat Malignant Mesothelioma | MT |
| 06-16 | Digia Unit to Provide Data Integration, AI Analytics for Finnish Health Sector Project | MT |
Company Valuation: Orion Oyj
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,119 | 7,179 | 5,509 | 6,005 | 8,944 | 9,706 | - | - |
| Change | - | 40.25% | -23.26% | 8.99% | 48.95% | 8.52% | - | - |
| Enterprise Value (EV) 1 | 5,010 | 7,060 | 5,603 | 6,126 | 9,088 | 9,605 | 9,393 | 9,139 |
| Change | - | 40.91% | -20.65% | 9.35% | 48.35% | 5.68% | -2.21% | -2.71% |
| P/E | 26.5x | 20.6x | 25.5x | 18.2x | 17.9x | 17.6x | 14.9x | 13.4x |
| PBR | 6.86x | 7.91x | 6.19x | 5.98x | 6.97x | 6.09x | 4.92x | 4.07x |
| PEG | - | 0.3x | -0.7x | 0.3x | 0.3x | 1.81x | 0.8x | 1.2x |
| Capitalization / Revenue | 4.92x | 5.36x | 4.63x | 3.89x | 4.73x | 4.67x | 4.13x | 3.83x |
| EV / Revenue | 4.81x | 5.27x | 4.71x | 3.97x | 4.81x | 4.62x | 3.99x | 3.6x |
| EV / EBITDA | 17.3x | 14.5x | 17.2x | 12x | 13.2x | 12.8x | 10.6x | 9.38x |
| EV / EBIT | 20.6x | 16.1x | 20.4x | 14.7x | 14.4x | 13.9x | 11.5x | 10.1x |
| EV / FCF | 38.5x | 21.7x | 105x | 29.7x | 41.5x | 19.9x | 18.7x | 15x |
| FCF Yield | 2.6% | 4.6% | 0.95% | 3.37% | 2.41% | 5.03% | 5.35% | 6.66% |
| Dividend per Share 2 | 1.5 | 1.6 | 1.62 | 1.64 | 1.8 | 1.907 | 2.113 | 2.358 |
| Rate of return | 4.11% | 3.12% | 4.13% | 3.83% | 2.83% | 2.77% | 3.07% | 3.42% |
| EPS 2 | 1.38 | 2.49 | 1.54 | 2.35 | 3.56 | 3.907 | 4.612 | 5.14 |
| Distribution rate | 109% | 64.3% | 105% | 69.8% | 50.6% | 48.8% | 45.8% | 45.9% |
| Net sales 1 | 1,041 | 1,341 | 1,190 | 1,542 | 1,890 | 2,080 | 2,352 | 2,537 |
| EBITDA 1 | 289.1 | 487.1 | 326.4 | 509.4 | 688.3 | 752 | 883.9 | 974.2 |
| EBIT 1 | 243.3 | 439.6 | 274.9 | 416.6 | 631.6 | 689 | 814.5 | 905.5 |
| Net income 1 | 193.8 | 349.5 | 216.8 | 329.9 | 500.3 | 549.5 | 649.2 | 724.1 |
| Net Debt 1 | -108.3 | -118.7 | 93.3 | 121.7 | 144.4 | -100.6 | -312.7 | -567.1 |
| Reference price 2 | 36.52 | 51.24 | 39.27 | 42.78 | 63.65 | 68.90 | 68.90 | 68.90 |
| Nbr of stocks (in thousands) | 140,563 | 140,202 | 140,351 | 140,501 | 140,693 | 140,866 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/13/24 | 2/25/25 | 2/12/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.63x | 4.62x | 12.77x | 2.77% | 11.05B | |
| 32.26x | 11.78x | 24.17x | 0.62% | 987B | |
| 25.55x | 5.89x | 16.01x | 2.23% | 576B | |
| 29.14x | 6.97x | 14.27x | 2.95% | 415B | |
| 17.33x | 4.31x | 10.6x | 3.08% | 320B | |
| 22.48x | 4.7x | 13.31x | 1.86% | 278B | |
| 21.11x | 5.46x | 13.24x | 2.93% | 279B | |
| 13.65x | 5.05x | 10.4x | 3.69% | 208B | |
| 22.56x | 6.05x | 10.56x | 2.91% | 187B | |
| -44.81x | 5.41x | 29.83x | 2.6% | 155B | |
| Average | 15.69x | 6.02x | 15.52x | 2.56% | 341.63B | |
| Weighted average by Cap. | 22.43x | 7.38x | 17.18x | 2.1% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORNBV Stock
- Valuation Orion Oyj
Select your edition
All financial news and data tailored to specific country editions
